ILMN Reported this cycle

Illumina

San Diego, CA Life Science Tools & CRO

AI-generated · informational only · not investment advice · verify before relying.

Latest analysis

Updated Aug 13, 2026

Illumina refinances $1B credit facility with five-year revolving commitment.

Illumina replaced its January 2023 credit facility with a new $1 billion senior unsecured revolving credit agreement maturing August 2031, featuring a maximum total leverage covenant and optional $500 million incremental capacity. As of the August 13, 2026 filing date, no borrowings were outstanding. The refinancing does not signal immediate capital deployment but repositions the company's liquidity runway and financial flexibility amid ongoing strategic execution.

Tone: neutral

Revenue

$4.3B

ILMN 10-K · FY 2025

Revenue FY2024

$4.4B

Headquarters

San Diego, CA

Profile

ILMN 10-K Item 1 · Feb 12, 2026

Illumina is a leading developer and manufacturer of sequencing and array-based genomic analysis solutions. The company serves research institutions, clinical laboratories, pharmaceutical companies, and academic centers globally. Its platforms enable applications spanning basic genomics research, clinical oncology, reproductive health, and agrigenomics.

Primary products

Next-generation sequencing instruments
Sequencing reagents and consumables
Genomics analysis software

Named competitors

10x Genomics Pacific Biosciences Oxford Nanopore Technologies Thermo Fisher Scientific

Revenue commentary · FY 2025

Total revenue declined from $4,372 million in fiscal 2024 to $4,343 million in fiscal 2025, driven by a decrease in service and other revenue partially offset by modest growth in product revenue.

The rest of ILMN is for subscribers

Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.

SeventhBiz analysis 6 signals 12 diligence answers 1 M&A transactions SWOT

View plans Sign in